Description

Edwards Lifesciences: A $2 Billion TMTT Target Frames The Next Phase

Edwards Lifesciences delivered steady financial performance in 2025, supported by continued expansion across its structural heart portfolio. Fourth-quarter sales rose 11.6% year-over-year to $1.57 billion, while full-year growth reached 10.7%, driven primarily by its transcatheter aortic valve replacement platform alongside mitral and tricuspid therapies and surgical valves. The transcatheter aortic valve replacement segment remained the central contributor, with quarterly sales increasing 10.6% to $1.16 billion. Growth was supported by long-term clinical data reinforcing durability and effectiveness, including extended follow-ups from major studies. Recent guideline updates in Europe and data from early intervention trials are expected to expand patient eligibility and influence treatment timing, supporting future demand. Market share also benefited from selective competitive exits in certain regions, while overall positioning remained stable. The company continues to focus on improving patient access through partnerships and education initiatives.